Henagliflozin is a pharmaceutical drug for the treatment of
type 2 diabetes.[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.[2][3]
Henagliflozin, like other drugs of the
gliflozin class, inhibits the transporter protein
sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels.[4]
References
^Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, et al. (August 2021). "Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial". Diabetes, Obesity & Metabolism. 23 (8): 1754–1764.
doi:
10.1111/dom.14389.
PMID33769656.
^He X, Liu G, Chen X, Wang Y, Liu R, Wang C, et al. (July 2023). "Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects". Clinical Therapeutics. 45 (7): 655–661.
doi:
10.1016/j.clinthera.2023.06.002.
PMID37451912.